Article

Current status of anti-obesity medications and performance, an EHR based survey

2024-12-03

Abstract excerpt

<h4>Background</h4> Over the past two decades, the Food and Drug Administration (FDA) has significantly increased the approval of anti-obesity medications (AOMs) for obesity management. Both FDA-approved AOMs (F-AOMs) and Off-label AOMs (O-AOMs) have gained popularity and demonstrated promising results in randomized clinical trials (RCTs). However, their effectiveness in real-world settings remains less understoo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6ebd168c-69c6-539e-85fb-060462332590
DOI: 10.1101/2024.12.02.24318314

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Current status of anti-obesity medications and performance, an EHR based surveyDOI 10.1101/2024.12.02.24318314Read

Real-World Effectiveness, Safety, and Use Patterns of GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes: A Nationwide Multicentre Community Pharmacy StudySemantic proximity Read

Toward Precision Obesity Pharmacotherapy: Using the Eating Behavior Phenotype Scale (EFCA) in Real-World Clinical PracticeSemantic proximity Read

Review of the Use of Digital Therapeutics for Obesity Treatment: Toward a Psychological Phenotyping.Semantic proximity Read

Pharmacogenomics of Anti-Obesity Drugs: A Bioinformatics ApproachSemantic proximity Read

Twelve-month analysis of real-world evidence from a commercial telehealth obesity treatment providerSemantic proximity Read

Deep phenotyping obesity using EHR data: Promise, Challenges, and Future DirectionsSemantic proximity Read

Real-World Weight Loss and Telehealth Platform Utilization Patterns of Long-Term GLP-1 Receptor Agonist Treatment of self pay patients : A Retrospective AnalysisSemantic proximity Read

Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotypingSemantic proximity Read

Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotypingSemantic proximity Read

Toward Precision Obesity Pharmacotherapy: Using the Eating Behavior Phenotype Scale (EFCA) in Real-World Clinical Practice.Semantic proximity Read

Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.Semantic proximity Read

Self-Reported Side Effects Among Reddit Users Taking Unapproved RetatrutideSemantic proximity Read